Comparison of Primary Extubation Failure Between NIPPV and NI-NAVA

February 17, 2020 updated by: University of Florida

Comparison of Primary Extubation Failure Between Non-invasive Positive Pressure Ventilation (NIPPV) and Non Invasive Neural Access Ventilatory Assist (NI-NAVA)

Extubation failure is a significant problem in preterm neonates and prolonged intubation is a well-documented risk factor for development of chronic lung disease. Out of the respiratory modalities available to extubate a preterm neonate; high flow nasal canula, nasal continuous positive airway pressure (nCPAP) and noninvasive positive pressure ventilation (NIPPV) are the most commonly used.

A recent Cochrane meta-analysis concluded that NIPPV has lower extubation failure as compared to nCPAP (30% vs. 40%)

NAVA (neurally adjusted ventilatory assist), a relatively new mode of mechanical ventilation in which the diaphragmatic electrical activity initiates a ventilator breath and adjustment of a preset gain (NAVA level) determines the peak inspiratory pressure. It has been reported to improve patient - ventilator synchrony and minimize mean airway pressure and ability to wean an infant from a ventilator. However till date there has been no head to head comparison of extubation failure in infants managed on NAVA with conventional ventilator strategies.

In this study the investigators aim to compare primary extubation failure rates in infants/participants managed by NIPPV vs. NI-NAVA (non invasive NAVA). Eligible infants/participants will be randomized to be extubated to predefined NIPPV or NI-NAVA ventilator settings and will be assessed for primary extubation failure (defined as reintubation within 5 days after an elective extubation).

Study Overview

Detailed Description

Mechanical ventilation is needed for most preterm infants to maintain adequate oxygenation and ventilation. However the coexistence of lung immaturity, weak respiratory drive, excessively compliant chest wall, and surfactant deficiency often contribute to dependency on mechanical ventilation during the first days or weeks after birth.

Prolonged mechanical ventilation is associated with high mortality and morbidities including ventilator-associated pneumonia, pneumothorax, and bronchopulmonary dysplasia (BPD). Each additional week of mechanical ventilation is reported to be associated with an increase in the risk of neurodevelopmental impairment. Reduction in the need and duration of invasive mechanical ventilation may potentially improve outcome of preterm infants.

Extubation failure has been independently associated with increased mortality, longer hospitalization, and more days on oxygen and ventilatory support. It is critical, therefore, to attempt extubation early and at a time when successful extubation is likely.

A recent Cochrane review compared the use of nasal intermittent positive pressure ventilation (NIPPV) with nasal continuous positive airway pressure (nCPAP) in preterm infants after extubation and found that NIPPV may be more effective than nCPAP at decreasing extubation failure.

The feasibility of NAVA use has been described in neonatal and pediatric patients. Several studies cite a decrease in peak inspiratory pressures, improved synchrony in triggering, and more appropriate termination of positive pressure support. Some studies have reported lower work of breathing, PaO2/FiO2 ratios (partial pressure of oxygen/ fractional inspired oxygen)and MAP. In addition, NAVA has been used for patients who "fight the ventilator," and the synchrony improves the ability to wean.

The use of NIV-NAVA in neonates has promise as a primary mode of ventilation to aid in the prevention of intubation and also maintaining successful extubation. Early extubation may be enhanced with NIV-NAVA of those neonates requiring intubation for numerous reasons. The ability to provide synchronous NIV allows clinicians the opportunity to extubate infants earlier with increased confidence than with previous post extubation support.

However there is lack of scientific evidence on extubation failure rates on NI-NAVA. Trials comparing NAVA to conventional ventilators with regard to ventilator associated lung injury, ventilator associated pneumonia and decreasing duration of time on the ventilator have not yet been reported.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Florida
      • Jacksonville, Florida, United States, 32207
        • University of Florida

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

10 months to 8 months (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Infants born between 24 weeks and ≤ 32 weeks completed gestational age or birth weight less than or equal to 1500 grams
  2. Postnatal age ≤ 14 days
  3. Inborn
  4. Mechanically ventilated for at least 12 hrs.
  5. Intubated within first 24 hrs. after birth
  6. Outborn infants intubated and transferred to UF within 24 hrs. after birth.

Exclusion Criteria:

  1. Outborn > 24hrs of age.
  2. Failed elective extubation prior to study enrollment
  3. Major congenital anomalies or known/suspected chromosomal anomalies
  4. Use of paralytics in previous 24 hrs.
  5. Participation in another randomized interventional trial
  6. Known or suspected phrenic nerve palsy or lesion
  7. Known or suspected diaphragmatic lesion
  8. Any contraindication to have a nasogastric or orogastric tube placement

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: NI-NAVA
  • Wait to meet extubation criteria within 14 days postnatal age
  • Pre-extubation mode of invasive ventilation will be per physician discretion (NAVA, CMV, high frequency oscillator ventilation (HFOV) or high frequency jet ventilation (HFJV)) Pi to determine eligibility or exclusion
  • Randomize to either NIPPV or NI-NAVA, 1:1 randomization
  • PI will not be blinded to the intervention (not feasible)
  • If extubating to NAVA then place the catheter to optimize position and Edi 1 hr. prior to planned extubation.
  • ABG or CBG to be obtained at 4 hrs. post extubation
  • NI-NAVA settings will be weaned or increased as the clinical situation demands and outlined in the protocol
Infant will be extubated to NAVA, settings based per protocol
Active Comparator: NIPPV

Wait to meet extubation criteria within 14 days postnatal age

  • Pre-extubation mode of invasive ventilation will be per physician discretion (NAVA, CMV, high frequency oscillator ventilation (HFOV) or high frequency jet ventilation (HFJV)) PI to determine eligibility or exclusion
  • Randomize to either NIPPV or NI-NAVA, 1:1 randomization
  • PI will not be blinded to the intervention (not feasible)
  • ABG or CBG to be obtained at 4 hrs. post extubation
  • NIPPV settings will be weaned or increased as the clinical situation demands and outlined in the protocol
Infant will be extubated to NIPPV, settings detailed in protocol

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Extubation success
Time Frame: 5 days
assess how many infants stayed extubated at 5 days after extubation
5 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Bronchopulmonary dysplasia (BPD)
Time Frame: until discharge / 36 weeks post menstrual age
based on NIH guidelines
until discharge / 36 weeks post menstrual age
Ventilator Days
Time Frame: until discharge / 36 weeks post menstrual age
days on positive pressure ventilation
until discharge / 36 weeks post menstrual age
NICU length of stay
Time Frame: until discharge / 36 weeks post menstrual age
discharge or death or transfer
until discharge / 36 weeks post menstrual age
Patent ductus arteriosus (PDA)
Time Frame: until discharge / 36 weeks post menstrual age
echo diagnosed/confirmed
until discharge / 36 weeks post menstrual age
Necrotizing enterocolitis (NEC
Time Frame: until discharge / 36 weeks post menstrual age
confirmed on Xray
until discharge / 36 weeks post menstrual age
Late onset sepsis
Time Frame: until discharge / 36 weeks post menstrual age
only culture proven
until discharge / 36 weeks post menstrual age
Gastrointestinal perforation
Time Frame: until discharge / 36 weeks post menstrual age
confirmed on X-ray or surgical exploration
until discharge / 36 weeks post menstrual age
Mortality
Time Frame: until discharge / 36 weeks post menstrual age
all causes within NICU stay
until discharge / 36 weeks post menstrual age
Extubation failure at 3 days
Time Frame: until discharge / 36 weeks post menstrual age
reintubation by 72 hrs. post extubation
until discharge / 36 weeks post menstrual age
Extubation failure at 7 days
Time Frame: until discharge / 36 weeks post menstrual age
reintubation by 72 hrs. post extubation
until discharge / 36 weeks post menstrual age
Pulmonary air leak
Time Frame: until discharge / 36 weeks post menstrual age
including pulmonary interstitial emphysema (PIE) pneumomediastinum and pneumothorax
until discharge / 36 weeks post menstrual age
Severe intraventricular hemorrhage
Time Frame: until discharge / 36 weeks post menstrual age
on cranial ultrasound, worst grade
until discharge / 36 weeks post menstrual age
Abdominal distension > 2cm from baseline and with signs necessitating cessation of feeds during the first 48 hrs. after extubation
Time Frame: until discharge / 36 weeks post menstrual age
during the first 48 hrs. after extubation
until discharge / 36 weeks post menstrual age
Retinopathy of prematurity (ROP)
Time Frame: until discharge / 36 weeks post menstrual age
ophthalmologic exam
until discharge / 36 weeks post menstrual age
Ventilator associated Pneumonia (VAP)
Time Frame: until discharge / 36 weeks post menstrual age
diagnosed based on tracheal culture + CXR changes + clinical worsening + treatment
until discharge / 36 weeks post menstrual age

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sanket Shah, MD, University of Florida

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 23, 2017

Primary Completion (Actual)

September 5, 2019

Study Completion (Actual)

September 5, 2019

Study Registration Dates

First Submitted

July 28, 2017

First Submitted That Met QC Criteria

August 1, 2017

First Posted (Actual)

August 8, 2017

Study Record Updates

Last Update Posted (Actual)

February 19, 2020

Last Update Submitted That Met QC Criteria

February 17, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Preterm Infant

Clinical Trials on NAVA

3
Subscribe